‘Innovation in emerging markets is not all about cost reduction’

Emerging markets are predicted to account for a third of global pharmaceutical spend by the end of next year – and seen as critical for the sustained growth of leading pharma companies


That's according to a new report, which says innovation and technology will be important differentiators as pharma organizations try to drive growth in developing countries.

The report summarizes the findings of a Cambridge Consultants.

The product design and development firm brought together senior personnel from both Indian and multinational pharma companies to debate whether emerging markets can be an opportunity to drive sustainable growth.

The consensus was that the term ‘emerging markets' covers nations in parts of Africa, the Middle East and South East Asia, as well as the more traditional countries of Brazil, Russia, India and China.

But all the delegates said emerging markets cannot be grouped into a single cluster to chalk out common strategies.


Previous 1 3 4 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email